In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant (pre-operative) pembrolizumab.
Endoscopic Ablation Reduces ‘Hunger Hormone,’ Yields Weight Loss in Early Trial
WASHINGTON — Endoscopic gastric fundus mucosal ablation (GFMA) as a means of reducing production of the hunger-modulating hormone ghrelin was technically feasible and safe in
May 22, 2024